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Abstract
Background: Systemic administration of cannabinoid agonists is known to reduce pain induced by bladder
inflammation and to modulate cystometric parameters in vivo. We have previously reported that intravesical
administration of a cannabinoid agonist reduces the electrical activity of bladder afferents under normal conditions.
However, the effects of local activation of bladder cannabinoid receptors on afferent activity during inflammation
are unknown. This study was aimed to assess the effects of intravesical administration of a cannabinoid agonist on
the discharges of afferent fibers in inflamed bladders ex vivo. We also characterized the expression of CB1 receptors
in the bladder and their localization and co-expression with TRPV1, a marker of nociceptive afferents.
Results: Compared to untreated animals, afferent fiber activity in inflamed bladders was increased for intravesical
pressures between 10 and 40 mmHg. Local treatment with a non selective cannabinoid agonist (AZ12646915)
significantly reduced the afferent activity at intravesical pressures above 20 mmHg. This effect was blocked by
AM251 but not by AM630 (selective for CB1 and CB2 respectively). Finally, CB1 was co-expressed with TRPV1 in
control and inflamed bladders.
Conclusion: These results demonstrate that sensitization of bladder afferents induced by inflammation is partly
suppressed by intravesical activation of cannabinoid receptors, an effect that appears to be mediated by CB1
receptors. Also, TRPV1 positive fibers were found to co-express CB1, supporting the hypothesis of a direct action of
the cannabinoid agonist on nociceptive afferents. Taken together, these results indicate a peripheral modulation by
the cannabinoid system of bladder hypersensitivity during inflammation.
Background
The role of the cannabinoid system in the regulation of
bladder function has attracted considerable interest in
the last few years [1]. Several studies have reported the
presence of cannabinoid receptors CB1 or CB2 mRNA
and/or protein in the bladder of rats [2], mice [3], mon-
keys[4] and humans[5]. The localization of CB1 recep-
tors has been described in the urothelium and in nerve
fiber structures of the suburothelium and the detrusor
[3,6,7]. Another study did not find CB1 immunoreactiv-
ity in the urothelium and nerve fibers but reported the
expression of CB2 in these structures [4]. However,
most previous studies have looked only at the efferent
functions of the bladder when studying the functional
activity of cannabinoid receptors. For instance, electri-
cally-evoked contractions of bladder preparations in
mice are reduced by CB1 activation [8,9]. The release of
CGRP evoked by capsaicin and ATP is also reduced by
activation of CB1 and CB2 in rats [6]. And cystometric
studies have shown that systemic administration of can-
nabinoid CB1 and CB2 agonists increases the micturition
threshold and voiding interval [10-12].
During pathological conditions there is a change in
the expression of cannabinoid receptors. CB1 mRNA
transcription was found to be increased in patients with
chronic bladder pain syndromes [13] and CB2 mRNA
and protein expressions are increased in rats with
bladder inflammation due to acrolein [2]. Cystometric
studies have also shown a reduction by cannabinoids of
bladder hyperactivity after inflammation [10,11,14].
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turpentine instillation is reduced after systemic adminis-
tration of cannabinoid agonists [15].
Although some of these cystometric and behavioral
effects of cannabinoids could involve the afferent compo-
nent of the bladder, the precise contribution of afferent
effects is difficult to ascertain because of the techniques
used and the systemic administration of the agonists. We
have previously shown that stimulation of cannabinoid
receptors reduces afferent activity in an electrophysiolo-
gical ex vivo preparation under normal conditions [3].
However, nothing is known about the responses to can-
nabinoid agonists of afferents from inflamed bladders.
The purpose of the present study was to assess the effect
of intravesical administration of a cannabinoid agonist on
afferent bladder activity after an acute inflammation
induced by cyclophosphamide (CYP). We used our ex
vivo bladder nerve preparation to evaluate the effects of
inflammation as well as the action of the intravesical
administration of a non-selective CB1-CB2 agonist on
afferent fiber activity. In another set of experiments, we
challenged this agonist with selective antagonists for CB1
and CB2 receptors (AM251 and AM630). Finally, to
assess if direct activation of CB1 receptors on bladder
afferents could mediate the effect of agonists, we looked
at this receptor expression in bladder tissue and its possi-
ble co-localization with TRPV1, a neuronal marker of
peptidergic afferent C-fibers in mice.
Results
Behavior
Mice receiving i.p. saline produced very few abdominal
contractions after the injection. Also, the number of mic-
turitions in these control animals was less than one during
each 20 minute period. Injection of cyclophosphamide
(300 mg/kg) i.p. induced an increase in abdominal con-
tractions that was statistically significant after 20 minutes
post-injection. The number of abdominal contractions
increased progressively reaching a plateau at 80 minutes
post-injection with about 12 contractions per 5 minute
period. Also, 60 minutes after injection, the number of
micturitions was significantly increased in animals receiv-
ing CYP compared to those receiving saline, reaching a
plateau of about 10 voids per 20 minute periods (Figure 1).
Electrophysiology
-Effect of cyclophophamide treatment on bladder afferents
Compared to normal bladders, cyclophosphamide treat-
ment did not change bladder compliance. The volume
needed to reach 40 mmHg was 117.9 ± 9.2 μl and 114.9 ±
12.8 μl for normal and inflamed bladders respectively
(Figure 2A). However, the average firing threshold of affer-
ents from inflamed bladders was significantly decreased
compared to our database of thresholds from normal
bladders (10.6 ± 0.56 and 6.5 ± 0.57 mmHg for normal
and CYP bladders respectively) (Figure 2C). Figure 3A
shows representative traces of single units responding to
distention of normal (left panel) and inflamed bladder
(pre-treatment, middle panel). The average activity of
afferent fibers after cyclophosphamide inflammation was
increased for intravesical pressures ranging from 10 to 40
mmHg. The maximal average activity was increased from
a b o u t1 1t o1 7s p i k e s / s( F i g u r e3 B ) .
-Effect of intravesical administration of a cannabinoid
agonist
The bolus administration of AZ12646915 (100 μM, 100 μl)
did not change bladder compliance (139.8 ± 16.2 and
146.5 ± 19.2 μl to reach 40 mmHg for pre- and post-drug
respectively) or the average threshold of firing of the affer-
ents (4.7 ± 1.0 pre-drug and 4.5 ± 0.9 mmHg post-drug)
(Figure 2B and 2D). A representative recording of a single
unit from an inflamed bladder before and after intravesical
treatment with AZ12696915 is shown in Figure 3A (mid-
dle and right panels). The maximal activity was decreased
by cannabinoid administration from 25 spikes/s to
12 spikes/s in this example. Note that most of the reduc-
tion occurred at higher intravesical pressures. The average
afferent activity was significantly reduced for intravesical
pressures above 20 mmHg (Figure 3 and Figure 4A). In
addition, the average firing rate after AZ12646915 in
inflamed bladders reached values similar to those of
normal bladders for intravesical pressures ranging from
25 to 40 mmHg (Figure 3).
-Effects of CB1 and CB2 antagonists on the response of
AZ12646915
The specificity of action of the cannabinoid agonist
AZ12646915 was assessed with two antagonists: AM251
and AM630 which are selective for CB1 and CB2 respec-
tively. The treatment with AM251 (100 μM) blocked the
reduction of afferent activity observed after AZ12646915
alone (Figure 4B). Furthermore, there was an increased
response of the bladder afferents for pressures going
from 20 to 30 mmHg. However, this suppression of inhi-
bition was not observed with the cannabinoid receptor
CB2 antagonist AM630 (100 μM). The afferent activity
after AZ12646915 + AM630 was reduced for intravesical
pressures above 15 mmHg which is similar to the effects
of the cannabinoid agonist alone (Figure 4C). The areas
under the curve (AUC) for pre- and post-treatments
were calculated. They showed an overall significant
reduction of about 20% of afferent activity for
AZ12646915 alone and AZ12646915 + AM630 while the
AUC tended to be increased (P = 0.0512) after the treat-
ment with AZ12646915 + AM251 (Figure 4D).
Immunofluorescence
The specificity of the antibodies was assessed with satur-
ating concentration of the immunogen peptides specific
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these blocking peptides prevented the immunofluores-
cence observed for CB1 and TRPV1 (Figure 5). CB1 recep-
tor immunoreactivity was found in the urothelium and in
nerve fibers structures of the suburothelium and of the
muscular layers. When looking at co-staining of CB1 +
TRPV1, in saline and CYP treated animals, we observed
co-localization in the urothelium and in nerve fiber struc-
tures from the suburothelial layer (Figure 6, arrowheads).
Discussion
Cannabinoid agonists have analgesic properties by acting
directly at the central nervous system as demonstrated
by intrathecal or intracerebroventricular administrations
[16-18]. However, targeting the peripheral cannabinoid
system for analgesia could be of clinical value since it
would eliminate the unwanted psychoactive effects. Per-
ipheral actions of cannabinoids on somatic pain have
also been described after topical administration [19], by
using compounds that do not cross the blood brain bar-
rier [20] or by genetic means using nociceptor-specific
deletion of CB1 receptors [21]. However, there is no
direct evidence of a peripheral action of cannabinoids
on the sensory innervation of internal organs that could
explain a purely local effect on visceral hypersensitivity.
One study showed that increased activity of mesenteric
afferents evoked by bradykinin could be reduced by sys-
temic administration of a CB2 receptor agonist [22].
Another report, using an in vitro mesenteric prepara-
tion, concluded that the afferent activity induced by bra-
dykinin or by mechanical distention was unchanged by
administration of the non selective CB1/CB2 agonist
WIN 55, 212-2, but reduced by a CB1 antagonist while
the opposite effect was observed after serotonin admin-
istration [23]. As for the bladder, only indirect measure-
ments of the effects of cannabinoids on its afferent
activity have been performed using behavioral assessment
[15,24] or cystometry [10,11,14]. These studies used sys-
temic administration of cannabinoids, which did not
exclude the effects of the compounds on the central ner-
vous system. Also, since it has been shown in vitro that
activation of cannabinoid receptors can reduce the con-
traction of the detrusor [8,9], the effects on motor activity
could explain the results observed in the behavioral and
cystometry studies. Therefore, the possible local and
direct action of cannabinoids on bladder afferent activity,
and hence on bladder pain, were still unknown.
Two main observations have been made in the present
study: i) intravesical administration of a cannabinoid ago-
nist reduced the sensitization of mouse bladder afferent
fibers after acute inflammation; an effect that appears to
be mediated through peripheral CB1 receptors only and
ii) cannabinoid CB1 expressing nerve fibers co-express
TRPV1 in the bladder. Therefore, the present results pro-
vide the first direct evidence that local activation of CB1
receptors reduce the inflammation-induced hypersensi-
tivity of sensory afferent fibers in the bladder.
Effects of acute cyclophosphamide inflammation on
behavior
As previously reported [25,26], systemic administration
of cyclophosphamide produced a substantial change in
the mice behavior. All animals displayed many abdominal
contractions that were almost absent in animals receiving
saline solution. In addition, we noticed an important
increase in micturitions up to about 10 voids per 20
Figure 1 Behavior observed after injection of cyclophosphamide. A) Abdominal contractions observed during 5 min periods every 20 min
post cyclophosphamide (CYP) or saline injection. B) Number of micturitions measured during 20 min periods every 20 min periods post CYP or
saline injection. Results are mean ± SEM (Saline n = 8, CYP n = 11, **P < 0.01, ***P < 0.001, t-test).
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hour observed in another study using cyclophosphamide
[27]. The average number of micturitions in the saline
group was low. The reason could be that non inflamed
mice urinated mostly during the habituation period
(60 minutes before injection) and tended to sleep during
the two consecutive hours. The clear nociceptive beha-
vior expressed by the animals after cyclophosphamide
injections allowed us to confirm that a painful inflamma-
tion was established before performing the ex vivo elec-
trophysiological experiments.
Effects of acute cyclophosphamide inflammation on
bladder afferent activity
Once the bladder inflammation was established we ana-
lyzed the electrophysiological properties of its afferents.
A few previous reports have described the effects of
cyclophosphamide inflammation on the activity of blad-
der afferents. One study showed that an acute treatment
with cyclophosphamide (two hours prior perfusion of
rats) increased Fos immunoreactivity in regions of the
spinal cord which receive afferent input from the blad-
der [28]. Other studies using patch clamp techniques
showed an increased excitability of dissociated dorsal
root ganglion neurons in vitro of rats having received a
prolonged treatment with cyclophosphamide [29,30].
Using a preparation similar to ours, Yu and de Groat
[31] have shown an increase of activity of afferent fibers
in rat pelvic nerve in response to isotonic bladder dis-
tension after cyclophosphamide injection. However, this
study did not look at discriminated single afferent fibers,
therefore their mechanical threshold could not been
Figure 2 Effects of cyclophosphamide and AZ12646915 on the bladder compliance and firing threshold of the afferent fibers. A and B)
Compliance of the bladder calculated as the volume infused to reach 40 mm Hg in normal (29 mice) and cyclophosphamide (CYP) (19 mice)
pooled groups (A) and pre- versus post-administration of AZ12646915 in CYP mice (7 mice) (B). C and D) Firing threshold (mm Hg) of afferent
fibers responding to bladder filling in normal (146 fibers, 52 mice) and CYP (63 fibers, 19 mice) pooled groups (C) and pre and post AZ12646915
in CYP mice (29 fibers, 7 mice). Results are mean ± SEM. Normal versus CYP analyzed with t-test (*** P < 0.001) (A and C). Pre- versus post-drug
analyzed with paired t-test (B and D).
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have been due to silent fibers that became responsive to
distension after inflammation [32,33].
We did not find any significant differences in bladder
compliance using the current ex vivo preparation. This
is surprising, since cyclophosphamide treatment has
been reported to change bladder compliance during
in vivo cystometry experiments [34] or to modulate the
electrical-evoked contractions of stripes of the detrusor
in ex vivo experiments [35,36]. However, our results
may be explained by the fact that in the present study
the bladder preparation was disconnected from any
efferent control of the detrusor. Therefore, we could
ascertain that afferent responses to distension after
cyclophosphamide treatment were not impaired by a
change of compliance in our model.
Figure 3 Effects of cyclophosphamide and AZ12646915 on afferent activity in response to mechanical distension. A) Representative
traces of one fiber activity in a normal mouse (left panel) and of another fiber from an inflamed mouse (CYP) before and after the intravesical
administration of the cannabinoid agonist AZ12646915 (100 μM) (middle and right panels). The superimposed waveforms of each action
potential are displayed in the boxes. B) Afferent activity (spikes/s) in response to an increase of intravesical pressure for normal and inflamed
(CYP) before and after administration of AZ12646915. Results are mean ± SEM, * P < 0.05, ***P < 0.001 for normal versus CYP (t-test) and
+ P < 0.05, ++ P < 0.01, +++ P < 0.001 versus CYP pre AZ12646915 (paired t-test). Normal: n = 32 fibers, 10 mice. CYP: n = 29 fibers, 7 mice.
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bladder afferents
Intravesical administration of the non selective CB1-CB2
agonist AZ12646915 reduced the afferent activity of
inflamed bladders. Interestingly, the reduction occurred
for high intravesical pressures above 20 mm Hg and
reached the spike rate of normal bladders for those
higher pressures. These effects are in accordance with
the absence of change of threshold after cannabinoid
administration. Again, although the effects of cannabi-
noids on motility have been described through CB1 in
mice using strips of bladders [8,9], those studies found
mostly a prejunctional effect of CB1 activation. This
effect was absent in the current ex vivo preparation
since it is disconnected from any efferent control. In
addition, we measured no change in the compliance
after the treatment with AZ12646915 which support the
hypothesis that the cannabinoid agonist did not act on
the detrusor. Therefore, we could conclude that we
observed a purely sensory effect. Also, the intravesical
administration of the cannabinoid agonist could reduce
a distribution to the muscular layer and prevent any
effect on bladder motility.
The expression of CB2 receptor in the bladder has
been described by others [2,6,12]. While a role of CB2
might be expected during inflammation, the reduction
of afferent activity by a cannabinoid agonist was not
modified by a pre-treatment of the CB2 antagonist
AM630, whereas it was blocked by AM251, a CB1
receptor antagonist. We measured only the afferent fiber
activity ex vivo once inflammation was established and
therefore we did not evaluate any anti-inflammatory
effects of the cannabinoid agonist in vivo or in a pre-
emptive fashion. In addition, our results are in line with
Figure 4 Activity of inflamed (CYP) bladder afferent fibers, normalized to the maximal activity of pre-drug stimulation. A) normalized
activity before and after AZ12646915 alone (n = 29 fibers, 7 mice). B) normalized activity before and after AZ12646915 + AM251 (n = 19 fibers,
6 mice), C) normalized activity before and after AZ12646915 + AM630 (n = 19 fibers, 6 mice) and D) represents the percentage of the area
under the curves from A, B and C. Data are mean ± SEM. Paired t-test was used for A, B and C and one sample t-test for D. * P < 0.05, **P <
0.01 and ***P < 0.001 versus pre-drug groups.
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Figure 5 Control for the selectivity of CB1 and TRPV1 receptors antibodies. Upper panels (A-D, green) show the immunoreactivity obtained
in normal bladder sections incubated with the CB1 antibodies alone (A, B) or with the specific blocking peptide (C, D). The lower panels (E-H,
red) show the reactivity obtained with TRPV1 antibodies alone (E, F) or with the specific blocking peptide (G, H). U = urothelium, L = lumen, SU
= suburothelial and M = muscular layers, scale bar = 20 μm.
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cannabinoid agonists have been shown to increase the
intercontraction interval and micturition threshold mea-
surements (which have a sensory component) in normal
and inflamed rats. The same predominant role of CB1
versus CB2 was also observed with antagonists in these
studies [10,11]. In contrast with these results, a recent
study looked at cystometric parameters after administra-
tion of cannabinor, a novel CB2 agonist in normal rats
[12]. The afferent components of cystometric measure-
ments were modulated by the highest dose of this ago-
nist. Therefore, a role for CB2 cannot be excluded.
Saline CYP 300 mg/kg
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Figure 6 Bladder immunoreactivity for CB1 receptor (A, B) and TRPV1 (C, D). Mice were injected with saline (control, A, C and E) or
cyclophosphamide (CYP, B, D and F) 300 mg/kg two hours before tissue harvest. Arrowheads = nerve fibres which co-express CB1 receptors and
TRPV1, U = urothelium, L = lumen, dotted line = separation between the suburothelial (SU) and the muscular (M) layers. The boxes focus on the
co-expression of CB1 with TRPV1 in fibers of the suburothelium layer, scale bar = 20 μm.
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antagonist was used to ascertain if the action of this drug
selective for bladder CB2 receptors. A possible explanation
for the role of CB2 observed in some cystometric studies
would be via an action on the detrusor muscle. Then, since
we measured solely the electrophysiological afferent activ-
i t y ,i tc o u l db et h er e a s o nw h yw ed i dn o ts e ear o l ef o r
CB2 in this study contrary to some cystometric study.
Hayn et al. [6] evaluated bladder afferent activity indir-
ectly by measuring CGRP release from dissected bladder
domes stimulated with a mix of capsaicin and ATP. They
observed a reduction of CGRP release after administra-
tion of a cannabinoid agonist. This reduction was absent
in the presence of CB1 or CB2 antagonists. Overall CGRP
release depends on afferent activity but also on the con-
trol of exocytosis of neuronal vesicles [37]. Therefore,
taking our results into account, the difference of effect of
cannabinoid receptors could be attributed to the fact that
neuronal electric activity would be mediated by CB1
alone while the release of CGRP from neuronal vesicle
could be modulated by both cannabinoid receptors.
However, this is purely speculative especially since the
expression of CB2 i nn e u r o n si ss t i l lam a t t e ro fd e b a t e
[38]. Another hypothesis to explain CB2 modulation of
CGRP release is that it can be produced by other cell
types than neurons, especially immune cells [39-41]
which are known to express CB2 receptors [42,43].
Expression of CB1 receptors with TRPV1 in the mouse
urinary bladder
Since we observed a physiological effect mainly after CB1
receptor activation, immunofluorescence experiments
were performed to better characterize the expression of
this receptor. We looked at co-expression of CB1 protein
with TRPV1, which is a marker of peptidergic nocicep-
tors in mice [44]. As previously reported, we observed
CB1 immunoreactivity in the urothelium as well as in
nerve fiber structures of the sub-urothelium and the
muscular layers [3,6,7]. We did not observed obvious dif-
ferences (although not quantified) in the pattern of
expression of cannabinoid and TRPV1 receptors after
inflammation, which is not surprising as the observations
were made only 2 hours after the induction of the inflam-
matory process. Unmyelinated C-fibers are present in the
muscle, the suburothelium layer and close to urothelial
cells [45-47] locations that correspond to those of our
observations. Therefore, our electrophysiological results
can be explained by a direct action of cannabinoid ago-
nists on nociceptive fibers in the bladder modulating
their inflammation-induced sensitization. In addition, it
is known that TRPV1 plays a role in the bladder sensory
system [48,49] and that cannabinoid receptors can modu-
late TRPV1 activity [50,51]. Hence, we could speculate
that a possible way of modulating afferent activity could
be through an interaction of CB1 with TRPV1 in bladder
afferent fibers. The presence of CB1 in peptidergic fibers
in the bladder is also in line with a possible neuroinflam-
matory regulation as previously seen with the modulation
of neuropeptide release by cannabinoids [6].
In the present study, we also observed CB1 immuno-
fluorescence in urothelial cells themselves as previously
reported [3,5,6]. Those cells especially the umbrella cells
are important player in the bladder sensory transduction
processes [52]. Therefore, in addition to a direct action
on nerve fibers, another explanation for the reduction of
nerve activity after cannabinoid agonist administration
would be indirect through the urothelial cells.
Conclusion
We have shown that local activation of CB1 receptors
reduces the sensitization of bladder afferent neurons during
acute inflammation. In addition, the co-expression of CB1
with TRPV1 in nerve fibers confirms the presence of CB1
in peptidergic nociceptors and can therefore explain the
role of cannabinoid agonists in modulating the sensitization
of bladder afferents. Taken together these results support
the hypothesis of a peripheral modulation by the cannabi-
noid system of bladder hypersensitivity after inflammation.
Methods
Animals
Female C57BL/6 mice weighing 18-26 g (supplied by
Charles River Canada, St Constant, Qc, Canada) were
used in this study. Their estrous cycle was not controlled
for the following experiments. Animals were anesthetized
with urethane (2 g/kg) i.p. in saline solution (0.9% NaCl)
before cardiac perfusions or in order to dissect the blad-
der for electrophysiological studies. All experimental pro-
cedures followed the guidelines of the committee for
Research and Ethical Issues of the International Associa-
tion for the Study of Pain [53] and the project was
approved by the Animal Care and Use Ethics Committee
of McGill University. Care was taken to minimize the
number of animals used and to avoid their suffering.
Induction of inflammation
Mice received an injection of cyclophosphamide 300
mg/kg (i.p.) diluted in saline solution. This dose gener-
ates an inflammation after 2 hours post injection, as
previously described [25,26]. To ensure that inflamma-
tion due to cyclophosphamide was effective, some ani-
mals were observed for their behaviors during the 2
hours preceding the dissection of the bladder for elec-
trophysiological experiment.
Behavior
Mice were placed 60 minutes before injection to habituate
in an elevated plexiglass cage equipped with a mesh floor
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tion. To get baseline values, the behavior was observed for
abdominal contractions (brief retractions of the abdomen)
and the number of micturitions during the last 5 and 20
minutes of habituation respectively. A micturition episode
was defined as any obvious voiding of urine. The animals
received cyclophosphamide or its vehicle (saline) and the
counting of abdominal contractions (for 5 minutes peri-
ods) and micturitions (for 20 minutes periods) were then
repeated every 20 minutes during the 2 hours after injec-
tion. The animals were then anesthetized with urethane
and prepared for the dissection of the urinary bladder.
Electrophysiology
The mouse urinary bladder and surrounding tissues
were dissected and placed in a chamber where it was
continuously perfused with oxygenated (95% O2,5 %
CO2) Tyrode solution pH 7.4 (content in mM: NaCl
136.9; KCl 2.7; CaCl2 1.8, MgCl2 1; NaH2PO4 0.4;
NaHCO3 11.9 and Glucose 5.6). A fine triple-lumen
canula (combined diameter 0.9 mm) was inserted into
the bladder through the urethra. The canula was con-
nected to: i) a syringe pump (Harvard Apparatus, Hollis-
ton, Massachusetts, USA) to infuse Tyrode into the
bladder, ii) to a pressure transducer (P75, Hugo Sachs
Elektronik - Harvard Apparatus GmbH, March-Hugstet-
ten, Germany) to record intravesical pressure changes
and iii) to an outlet tube equipped with a three way
stopcock to block or release intravesical fluids from the
bladder. An additional canula (MicroFil MF34G 0.1 mm
I D ,W P I ,S a r a s o t a ,F L ,U S A ,d i a m e t e r0 . 1 6 4m m )w a s
added along the triple-lumen canula and connected to a
1 ml syringe to allow bolus application of drugs. The
urethra and the ureters were ligated to avoid leakage of
fluid from the urinary bladder.
Under a microscope, a branch of the pelvic nerve arising
from the urinary bladder was dissected. Nerve activity was
recorded from very fine filaments teased from the pelvic
nerve and sucked inside a glass suction electrode connected
to an Axon Instrument head stage (AI 402 × 50 Ultra low
noise differential amplifier, Axon Instrument) and an AC/
DC amplifier (CyberAmp 380, Axon Instrument). Signals
were amplified (250×) filtered (band-pass 10-10000 Hz)
and relayed to a noise eliminator (Hum Bug, Quest Scienti-
fic, Vancouver, Canada). The electrical activity of the nerve
and the intravesical pressure were digitized using a compu-
ter connected to a Micro 1401 MK II analog-to-digital
interface controlled with Spike 2 (version 6.13) software
(Cambridge Electronic Design, Cambridge, UK).
Mechanical stimulation of the bladder from normal or
inflamed animals was performed by a slow infusion of
Tyrode solution (0.1 ml/min) until the intravesical pres-
sure reached 40 mm Hg, then the pressure was released
by opening the outlet valve. Single unit discrimination
was performed by using the spike sorting function of
Spike2 software.
The effects of inflammation or drug administration on
bladder compliance were evaluated by calculating the
volume of Tyrode infused in the bladder to reach an intra-
vesical pressure of 40 mm Hg it was measured together
with the time required for the intravesical pressure and
the flow rate of the pump (0.1 ml/min). The thresholds of
firing of each afferent from inflamed bladders were calcu-
lated from the ramp of stimulation and compared with
our database of afferents from normal bladders.
After several (3-4) stimulations to ensure that the affer-
ent activity was stable, pharmacological assays were done
on inflamed bladder. In a first series of experiments, a
bolus (intravesical administration with the outlet valve
opened) of a non selective cannabinoid agonist
AZ12646915 (100 μl, 100 μM) dissolved in Tyrode + 1%
DMSO was administered between two inflations, with 20
minutes prior to the second stimulation. This dose was
selected as it was shown to be effective in reducing the
afferent activity in our previous study. In addition, we
observed a recovery and no effect of the vehicle [3]. To
assess the specificity of action of AZ12646915, CB1 recep-
tor antagonist AM251 (100 μl, 100 μM) or the CB2 recep-
tor antagonist AM630 (100 μl, 100 μM) were administered
5 minutes prior AZ12646915 in another series of experi-
ments using the same conditions of stimulation as above.
Both AM251 and AM630 are selective antagonists with
high affinity for CB1 and CB2 receptors respectively. The
dose of AM251 selected has been shown to be efficient in
blocking the effect of AZ12646915 in normal bladders [3],
the same dose was selected for AM630 since AZ12646915
has equal affinity for CB1 and CB2 receptors.
Afferent activity was measured as the number of
spikes/s counted at every 5 mm Hg intervals during each
ramp of stimulation going from 0 to 40 mm Hg. Agonist
and antagonists effects were measured using the normal-
ized activity: each point of the ramps of pressure (pre and
post-drug) was expressed as a percentage of the maximal
activity recorded in the pre-drug stimulation.
Immunofluorescence
A vascular rinse was performed by transcardial perfusion
with 50 ml of PBS 0.1 M + 1 UI heparin/ml followed by
200 ml of PBS + 4% paraformaldehyde as a fixative solu-
tion. The bladder was harvested and placed in the same
fixative solution during 3 hours at +4°C then transferred in
PBS 0.1 M + 30% sucrose overnight at +4°C. After permea-
bilization (PBS, 10% Normal Goat Serum (NGS), 0.25%
TRITON, 0.05% NaN3) and saturation with PBS + 20%
NGS, cryostat sections (12 μm) of the bladder were incu-
bated 48 h at +4°C with the primary antibodies solution:
anti CB1 raised in rabbit and anti TRPV1 raised in gui-
nea pig (Table 1). After rinsing, the sections were
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with fluorescein isothiocyanate (FITC, 488 nm) and
with goat anti guinea pig IgG (1:600) conjugated with
T e x a sr e d( 5 6 8n m )1ha tR T .M o u n t e ds l i d e sw e r e
observed under a Zeiss Axioplan 2 Imaging fluores-
cence microscope and images were captured by a digi-
tal camera AxioCam HRc (Zeiss, Canada).
Microphotographs were obtained with ×20 objectives.
Negative controls were sections incubated with the
primary antibodies preadsorbed with their respective
blocking peptide (Table 1) and the time of exposure
setting was constant during the acquisition of images.
Background subtraction and merging of images were
performed with the program Image J [54].
Chemicals
The cannabinoid compound used in this study,
AZ12646915 (Astra Zeneca R&D, Montreal, Canada)
has equal affinity for both human CB1 and CB2 receptor
(Ki = 17 nM and 16 nM respectively). It was selected
for its good solubility (up to 150 μM) in aqueous solu-
tion in order to prevent as much as possible precipita-
tion in the tubing. The cannabinoid receptors
antagonists AM251 and AM630 were purchased from
Tocris Bioscience (Ellisville, USA). Cyclophosphamide
was purchased from Sigma-Aldrich (Canada). Salts used
for the solutions were all purchased from ACP chemi-
cals (Montreal, Canada).
Statistics
Differences between normal and inflamed animals
were assessed with t-test for the behavior and Mann-
Whitney test for spike rate. Effects of drugs were eval-
uated with paired t-tests (Wilcoxon matched pairs
test). One sample t-test (versus a theoretical mean of
100) was used for the change of activity measured
with the area under the curves for the antagonists
study. P < 0.05 was considered statistically significant.
Statistical analyses were performed using GraphPad
Prism version 5.01 for Windows, GraphPad Software,
San Diego California USA.
List of abbreviations
CB1: receptor: cannabinoid receptor 1; CB2: receptor cannabinoid receptor 2;
CGRP: calcitonin gene related peptide; CYP: cyclophosphamide; i.p.:
intraperitoneal; TRPV1: transcient receptor potential vanilloid 1.
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